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IMPORTANCE Secretory phospholipase A2 (sPLA2) generates bioactive phospholipid products
implicated in atherosclerosis. The sPLA2 inhibitor varespladib has favorable effects on lipid
and inflammatory markers; however, its effect on cardiovascular outcomes is unknown.
OBJECTIVE To determine the effects of sPLA2 inhibition with varespladib on cardiovascular
outcomes.
DESIGN, SETTING, AND PARTICIPANTS A double-blind, randomized, multicenter trial at 362
academic and community hospitals in Europe, Australia, New Zealand, India, and North
America of 5145 patients randomized within 96 hours of presentation of an acute coronary
syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment
between June 1, 2010, andMarch 7, 2012 (study termination onMarch 9, 2012).
INTERVENTIONS Participants were randomized to receive varespladib (500mg) or placebo
daily for 16 weeks, in addition to atorvastatin and other established therapies.
MAIN OUTCOMES ANDMEASURES The primary efficacymeasure was a composite of
cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable
angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival
status was also evaluated.
RESULTS At a prespecified interim analysis, including 212 primary end point events, the
independent data and safety monitoring board recommended termination of the trial for
futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with
varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25;
95% CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78
[3.4%] vs 47 [2.2%]; HR, 1.66; 95% CI, 1.16-2.39; log-rank P = .005). The composite
secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients
(4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95%
CI, 1.02-1.82; P = .04).
CONCLUSIONS AND RELEVANCE In patients with recent ACS, varespladib did not reduce the
risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2
inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse
cardiovascular outcomes after ACS.
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D espiteahigh rateofuseof contemporary therapies,pa-tientswith acute coronary syndrome (ACS) face a sub-stantial risk of early, recurrent adverse cardiovascu-
lar events.1 Increasing evidence supports a potential role of
inflammation in theprogressionandclinical instabilityof coro-
naryheartdisease.2Necropsy studies show inflammatorycells
within atherosclerotic plaques,3 and clinical outcomes trials
show an association between systemic inflammatory mark-
ers andcardiovascular risk.4Conversely, reductions in inflam-
matory markers associate with reductions in cardiovascular
events in clinical trials and may contribute to the benefit of
statins.4 These observations provide a rationale to test novel
agents that target specific inflammatory factors implicated in
atherosclerosis todetermine if it reduces cardiovascular risk.5
The secretory phospholipase A2 (sPLA2) family of en-
zymes hydrolyze fatty acids of glycophospholipids, generat-
ing bioactive lipid species involved in inflammation.6 How-
ever,althoughsomesPLA2 isoformsareproatherogenic (groups
IIA and V), other isoforms are protective (group X).7 Consid-
erable evidence implicates a potential role for groups IIA and
V sPLA2 in cardiovascular disease.Higher circulating levels of
sPLA2-IIA concentration and activity associate with cardio-
vascular risk in asymptomatic individuals and patients with
established coronary disease.8 Pathologic studies demon-
strate the presence of sPLA2 isoforms groups IIA, III, V, and X
inatherosclerotic lesionsandmyocardial regions thathavesus-
tained ischemic injury.6,9,10 These observations have stimu-
lated interest in thepotential valueof sPLA2 inhibitionasa car-
dioprotective strategy.5
Varespladib methyl is a nonspecific pan-sPLA2 inhibitor
with favorable effects on atherosclerotic lesions in animal
studies.11 Initial studies demonstrated that varespladib re-
duced levelsof sPLA2-IIAbymore than90%, inaddition to low-
ering low-density lipoprotein cholesterol (LDL-C) and C-
reactiveprotein (CRP) inpatientswith stable coronarydisease
andACS.12-14 TheVascular InflammationSuppression toTreat
Acute Coronary Syndrome for 16Weeks (VISTA-16) studywas
designed to evaluate the effects of varespladib on cardiovas-
cular risk in patients with ACS.15
Methods
Study Population
Details of the studydesign and studyprotocol havebeenpub-
lished previously.15 Patients aged 40 years or older hospital-
izedwithanACSwhoprovidedwritten, informedconsentwere
eligible to participate. Documentation of ACS required either
(1) elevationofbiomarkersaccompaniedbysymptomsofacute
myocardial ischemia and/or new or presumed new ischemic
electrocardiographic abnormalities or (2) symptoms in com-
bination with new or presumed new electrocardiographic
changes inpatientswithoutelevatedbiomarkers.Patientswere
also required to have 1 additional risk factor for recurrent
events, including diabetes, metabolic syndrome, a high-
density lipoprotein cholesterol (HDL-C) level of less than 42
mg/dL (to convert tomillimoles per liter,multiply by 0.0259),
calculated glomerular filtration rate of less than 60 mL/min,
peripheral vascular disease, prior history of ischemic stroke,
or transient ischemicattack,myocardial infarction(MI),orcoro-
nary revascularization. Patients were excluded from enroll-
ment if LDL-C measured before the index ACS event was not
at target levels according to local guidelines, despite current
treatment with the maximum labeled dose of a statin. Other
keyexclusioncriteria includedadvancedcongestiveheart fail-
ure, glycated hemoglobin value of at least 11% (to convert to
proportion of total hemoglobin, multiply by 0.01), malig-
nancy, severe liver or renal disease, malignancy, statin intol-
erance, and fasting triglyceride levels of at least 400mg/dL (to
convert to millimoles per liter, multiply by 0.0113).
Study Procedures
The protocol specified that enrolled patients be treated with
individualized, evidence-basedmanagement ofACSs, includ-
ing diet and atorvastatin at a dose of at least 20 mg. Patients
whometall inclusioncriteriawere randomizedwithin96hours
of presentation of the index event in a 1:1 ratio to treatment
withvarespladib (500mg/d) ormatchingplacebo, stratifiedby
useof any lipid-modifying therapybefore the indexevent and
the type of qualifying index event (ST-elevation MI [STEMI],
non–ST-elevationMI, or unstable angina). Any clinically indi-
cated coronary revascularization during the index event was
performed before randomization. Patients reported for study
visits at weeks 1, 2, 4, 8, and 16 during the treatment phase.
Patients with an LDL-C level of at least 100mg/dL (to convert
to millimoles per liter, multiply by 0.0259) at week 8 under-
went atorvastatindose escalation. Telephone follow-up to as-
certain vital status was scheduled to occur 6 months follow-
ing cessation of study drug.
Study Outcomes
The primary efficacy outcomewas a composite of cardiovas-
cular mortality, nonfatal MI, nonfatal stroke, or unstable an-
ginawith evidenceof ischemia requiringhospitalization. Sec-
ondary efficacy outcomes included the composite of
cardiovascularmortality,nonfatalMI,andnonfatal stroke;each
component of the primary outcome; total mortality; and
changes in circulating lipid and inflammatorymarkers. All in-
vestigator-reported outcomes were adjudicated by a central
committeeat theClevelandClinicCoordinatingCenter forClini-
cal Research (C5Research).
Statistical Analysis
Primary efficacy analysis was based on time to first occur-
rence of any positively adjudicated primary end point event
by intention-to-treat, including all events in all patients from
randomization to trial termination. The trial was designed to
enroll6500patients,assumingan8.5%primaryendpointevent
rate in the placebo group,with 80%power to detect a 25% re-
duction in the relative risk of the varespladib group, necessi-
tating the adjudicationof 385primaryendpoint events.An in-
terim end point analysis for futility was specified at
approximately 50%of the requiredprimary endpoint events.
Estimates of hazard ratios (HRs) and 95% CIs for varespladib
compared with placebo were calculated by Cox proportional
hazards regressionmodels. Continuous data are presented as
Varespladib and Cardiovascular Events Original Investigation Research
jama.com JAMA January 15, 2014 Volume 311, Number 3 253
Downloaded From:  by a Universita Degli Studi La Sapienza Roma User  on 09/23/2018
Copyright 2014 American Medical Association. All rights reserved.
mean(SD),unlessotherwise indicated.Race/ethnicitywasself-
reported by participants. Significance testing was performed
using 2-sided tests (α = .05) using SAS version 9.2 (SAS Insti-
tute). Additional analyticalmethods are described in the pre-
viously published study protocol.15
Results
Study Population
A total of 5145 patients were enrolled at 362 sites in 17 coun-
tries between June 1, 2010, andMarch7, 2012, andentered into
the intention-to-treat analysis. The patient disposition dur-
ing the study is shown in Figure 1. The qualifying ACS event
wasbiomarkerpositive in85%of thepatients. Themedian (in-
terquartile range [IQR]) time from presentation with the in-
dex event to randomization and first study drug administra-
tionwas 57 (39-76) hours. Baseline characteristics of patients
at randomizationwerewellmatched in the2 treatment groups
(Table 1). A high rate of cardiovascular risk factors and estab-
lishedatheroscleroticdiseasewasobserved inbothgroups.Be-
fore the indexACSevent, 36%ofpatientshadbeentreatedwith
a lipid-modifying agent. At randomization, patientswerewell
treated in both groups with a high rate of use of antiplatelet
agents, statins, β-blockers, angiotensin-convertingenzyme in-
hibitors, or receptor blockers (see eTable 1 in the Supple-
ment). Coronary revascularization in response to the index
event was performed in 80% of the patients. At randomiza-
tion, mean LDL-C was 105 mg/dL and HDL-C was 43 mg/dL.
Median (IQR)CRPwas10.4 (4.0-28.7)mg/L in theplacebogroup
and 11.4 (4.5-33.0)mg/L in the varespladib group. (To convert
CRP to nmol/L, multiply by 9.524.)
On March 9, 2012, at the prespecified interim analysis,
when 212 primary outcomes had been recorded in 5012 ran-
domized patients, the independent data and safety monitor-
ingboard recommended terminationof the trial for futility ac-
cording to predetermined criteria. The executive steering
committee and sponsor (Anthera Pharmaceuticals) accepted
this recommendationandterminatedthetrialonthisdate,with
median (IQR) patient follow-up of 16.1 (13.4-16.4) weeks. Pa-
tients were treated for a mean (SD) of 13.4 (4.4) weeks. The
mean (SD) follow-up of patients for the treatment periodwas
13.5 (4.6) weeks. All 5145 patients were included in the 16-
week analysis. Time to eventwas calculated fromrandomiza-
tiondate to thedateof theevent, or censoredat the last known
follow-up for each patient if no event occurred. Only 1588 pa-
tients were contacted for the 6-month assessment.
Before study termination, premature discontinuation of
treatment for reasons other than death occurred in 11.0% of
the patients receiving varespladib and 10.4% of the patients
receiving placebo. During treatment, 96% of patients in both
groups remained at least 80%adherentwithprescribed study
drug doses. In the varespladib and placebo groups, 4.2% and
3.7%, respectively, of patientswithdrew consent and an addi-
tional 0.8%and 1.1%, respectively,were lost to follow-upwith
unknown final vital status.
Biochemical Parameters
Changes in biochemical parameters during the course of the
studyareshowninFigure2. Perprotocol, atorvastatinwasused
Figure 1. Flow of Patients Through the Trial
5391 Patients screened and assessed
for eligibility
246 Excluded (did not meet inclusion
criteria or met exclusion criteria) 
5145 Randomized
795 Included in 6-mo follow-up 793 Included in 6-mo follow-up
2573 Randomized to receive placebo
2573 Received placebo as randomized
2572 Randomized to receive varespladib
2572 Received varespladib as randomized
326 Discontinued placebo early
37 Adverse effects
13 Nonadherence
32 Lost to follow-up
104 Patient requested to withdraw
7 Principal investigator’s decision
2 Sponsor’s request
11 Atorvastatin outside of specified
timepoint or discontinued
17 Withdrawn secondary to ongoing
adverse event
1 LDL-C ≥100 at week 8 and received
maximum dose of atorvastatin
102 Other
368 Discontinued varespladib early
73 Adverse effects
25 Nonadherence
26 Lost to follow-up
116 Patient requested to withdraw
15 Principal investigator’s decision
1 Sponsor’s request
10 Atorvastatin outside of specified
timepoint or discontinued
10 Withdrawn secondary to ongoing
adverse event
1 LDL-C ≥100 at week 8 and received
maximum dose of atorvastatin
91 Other
2573 Included in primary analysis
4 Excluded (no data available)
2572 Included in primary analysis
6 Excluded (no data available)
LDL-C indicates low-density
lipoprotein cholesterol.
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innearlyall patients,withamediandosageof40mg/d.Slightly
fewer than 20% of patients received 80 mg/d. Between ran-
domization and week 16 of the study, LDL-C decreased by
28.8% in thevarespladib groupand25.1% in theplacebogroup
(P = .008). Atweek 16, themean LDL-Cwas 69.1mg/dL in the
varespladib group and 73.8mg/dL in the placebo group. Dur-
ing assigned treatment, levels of triglycerides and HDL-C did
not differ between groups. The CRP levels were initially very
Table 1. Clinical Baseline Characteristics of Patients TreatedWith Placebo or Varespladib
Characteristicsa Placebo (n = 2573) Varespladib (n = 2572)
Age, mean (SD), y 60.7 (9.8) 61.0 (10.0)
Female sex 660 (25.7) 691 (26.9)
Race/ethnicity
White 2277 (88.5) 2274 (88.4)
Asian 226 (8.8) 221 (8.6)
Black 30 (1.2) 433 (16.8)
Otherb 41 (1.6) 33 (1.3)
Region of enrollment
North America 528 (20.8) 535 (20.8)
Western Europe and Lebanon 315 (12.2) 323 (12.6)
Eastern Europe 1422 (55.3) 1388 (54.0)
Asia 215 (8.4) 213 (8.3)
Australia and New Zealand 93 (3.6) 113 (4.4)
Cardiovascular risk factors
Hypertension 1977 (77.8) 1911 (75.2)
Diabetes 803 (31.3) 801 (31.3)
Hypercholesterolemia 1292 (50.9) 1255 (49.3)
Present smokerc 860 (33.6) 854 (33.4)
Metabolic syndrome 1587 (64.3) 1589 (64.2)
Cardiovascular disease history
Myocardial infarction 743 (29.6) 769 (30.2)
PCI 476 (18.6) 453 (17.7)
CABG surgery 182 (7.1) 161 (6.3)
Stroke 123 (4.8) 128 (5.0)
Peripheral arterial disease 177 (6.9) 179 (7.0)
Body mass index, mean (SD)d 29.6 (5.1) 29.8 (5.4)
Prior lipid-modifying therapy 934 (36.5) 917 (35.8)
Index diagnosis
STEMI 1207 (46.9) 1216 (47.4)
NSTEMI 976 (38.0) 960 (37.4)
Unstable angina (biomarker negative) 388 (15.1) 392 (15.3)
Index event to randomization, median (IQR), h 57.0 (39.1-75.6) 57.6 (38.7-76.7)
PCI or CABG surgery for index event 1573 (80.3) 1656 (82.8)
Medications at randomization
Aspirin 2348 (91.3) 2362 (91.8)
Clopidogrel, ticlopidine, or prasugrel 1960 (76.2) 1956 (76.0)
β-Blocker 2158 (83.9) 2131 (82.9)
ACE inhibitor or ARB 2124 (82.5) 2116 (82.3)
Biochemical parameters at randomization, mean
(SD), mg/dL
LDL-C 105.1 (43.1) 105.0 (43.3)
HDL-C 43.2 (10.9) 43.3 (11.2)
Triglycerides 153.0 (115.0-213.0) 154.0 (115.0-207.0)
C-reactive protein, median (IQR), mg/L 10.4 (4.0-28.7) 11.4 (4.5-33.0)
Concomitant atorvastatin dose, mg
20 1217 (47.9) 1192 (46.8)
40 827 (32.6) 916 (36.0)
80 495 (19.5) 438 (17.2)
Abbreviations: ACE,
angiotensin-converting enzyme;
ARB, angiotensin receptor blocker;
CABG, coronary artery bypass graft;
HDL-C, high-density lipoprotein
cholesterol; IQR, interquartile range;
LDL-C, low-density lipoprotein
cholesterol; NSTEMI,
non–ST-segment elevation
myocardial infarction; PCI,
percutaneous coronary intervention;
STEMI, ST-segment elevation
myocardial infarction.
SI conversions: To convert HDL-C and
LDL-C tommol/L, multiply by
0.0259. To convert triglycerides to
mmol/L, multiply by 0.0113. To
convert C-reactive protein to nmol/L,
multiply by 9.524.
a Data are presented as No. (%)
unless otherwise specified.
bOther included those individuals
who did not identify themselves as
white, Asian, or black.
c Indicates smokes currently.
d Calculated as weight in kilograms
divided by height in meters
squared.
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high in both groups due to the indexACS event. Between ran-
domization and week 16, CRP decreased by 85.0% in the va-
respladib group and 82.1% in the placebo group (P = .008). At
week 16, median CRP was 1.4 mg/L in the varespladib group
and 1.5 mg/L in the placebo group.
Clinical Outcomes
Theprimaryoutcomeof cardiovascularmortality,nonfatalMI,
nonfatal stroke, or unstable angina requiring hospitalization
occurred in6.1%ofpatients treatedwithvarespladib and5.1%
of patients treated with placebo (HR, 1.25; 95% CI, 0.97-1.61;
log-rank P = .08) (Table 2). The composite secondary out-
come of cardiovascular mortality, MI, and stroke occurred in
4.6% of patients in the varespladib group and 3.8% of pa-
tients in theplacebogroup (HR, 1.36;95%CI, 1.02-1.82;P = .04).
This was due primarily to a greater incidence of MI in the va-
respladib group compared with the placebo group (3.4% vs
2.2%; HR, 1.66; 95% CI, 1.16-2.39; P = .005) (Figure 3). Cardio-
vascularmortality at the endof the randomized treatmentpe-
riodwasnonsignificantlygreater in thevarespladibgroup(1.5%
vs1.4%;P = .54), althoughrisksof stroke (0.4%vs0.6%;P = .81)
andhospitalization for unstable angina (1.9%vs 1.4%;P = .47)
were similar in both groups. Therewas no subgroup inwhich
varespladib reduced risk.However, greater ratesofMIwithva-
respladibwere observed inpatientswhodidnot undergoper-
cutaneous coronary intervention, meeting statistical signifi-
cance for heterogeneity (P = .04). Furthermore, there was a
higher rate ofMI associatedwith varespladib among patients
whose indexeventwasnotaSTEMI,althoughthisdidnot reach
statistical significance (P = .06 for heterogeneity) (Figure 4).
At 6 months after discontinuation of study treatment, all-
causemortality in thosepatientswhose survival statuswases-
tablished was 2.7% in the varespladib group and 2.0% in the
placebo group (P = .15).
Safety
Numbers of adverse events and serious adverse events are re-
ported ineTable2 in theSupplement.Discontinuationof study
treatment for adverse events occurred in 2.8% of patients in
thevarespladibgroupand1.4%ofpatients in theplacebogroup.
Therewas an excess of alanine transaminase elevationsmore
than 3 times the upper limit of normal during the treatment
Figure 2. Median Levels of Lipid Parameters and Log CRP in Patients TreatedWith Placebo and Varespladib
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phase with varespladib (38 patients) compared with placebo
(6 patients), with no evidence of concomitant bilirubin eleva-
tions. Varespladib had no effect on renal function or on cre-
atine kinase levels.
Discussion
Despite experimental andobservational clinical data suggest-
ing that pan-inhibition of sPLA2 would exert beneficial car-
diovascular effect, theVISTA-16 trial provides evidence to the
contrary.Despite lowerachieved levelsofLDL-CandCRP, there
was no evidence of a beneficial reduction in the primary car-
diovascular outcome. In contrast, treatmentwith varespladib
caused an excess of MI and the composite of cardiovascular
mortality, MI, and stroke. Consequently, these findings sug-
gest that short-termsPLA2 inhibitionwithvarespladib isharm-
ful following ACS.
The lackofany indicationofcardiovascularbenefitwithva-
respladibcontradicts thefavorableeffectsoncardiovascularbio-
markers inpatientswithACS. Initial clinicalexperiencewithva-
respladib consistentlydemonstratedbeneficial effects on lipid
and inflammatorybiomarkers,which theoretically shouldhave
translated toa lowerpropensity toplaque rupture.12-14Wecon-
ducted the VISTA-16 trial because of the established link be-
tween sPLA2 and vascular inflammation, as well as preclinical
evidence forbenefit in ischemia reperfusion injury.5 Favorable
effects of varespladib on LDL-C and CRP were again demon-
strated in the present trial, suggesting that other unfavorable
consequencesof sPLA2 inhibitionor otherunmeasuredeffects
of varespladib influenced the clinical outcomes of treatment.
Possibleexplanations for theunfavorableoutcomes includepo-
tentially inadequate penetration of varespladib into vascular
cells to inhibit pro-inflammatory intracellular mediators. Al-
ternatively, varespladibmayhaveabrogated theeffectsofboth
pro-atherogenic (IIA and V) and antiatherogenic sPLA2
Figure 3. Kaplan-Meier Survival Curves for the Primary Composite Outcome andMyocardial Infarction in Patients TreatedWith Placebo
and Varespladib
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The primary efficacy outcome was a composite of cardiovascular mortality, non-
fatal myocardial infarction, nonfatal stroke, and unstable angina with evidence
of ischemia requiring hospitalization at 16 weeks. Patients were randomized to
receive either varespladib (500mg/d) or placebo for 16 weeks. HR indicates
hazard ratio. Y-axis scale shown in blue indicates range from 0% to 4%.
Table 2. Cardiovascular Outcomes in Patients TreatedWith Placebo or Varespladib
Outcomes
Placebo
(n = 2573)
Varespladib
(n = 2572)
Hazard Ratio
(95% CI)
P
Value
Primary outcomea 109 (5.1) 136 (6.1) 1.25 (0.97-1.61) .08
All-cause mortality, myocardial infarction,
stroke, unstable angina with evidence
of ischemia requiring hospitalization
110 (5.1) 140 (6.3) 1.28 (0.996-1.64) .05
Cardiovascular mortality, myocardial infarction,
and stroke
79 (3.8) 107 (4.6) 1.36 (1.02-1.82) .04
All-cause mortality 33 (1.5) 41 (1.7) 1.25 (0.79-1.98) .35
Cardiovascular mortality 32 (1.4) 37 (1.5) 1.16 (0.73-1.87) .54
Myocardial infarction 47 (2.2) 78 (3.4) 1.66 (1.16-2.39) .005
Unstable angina with evidence of ischemia
requiring hospitalization
32 (1.4) 38 (1.9) 1.20 (0.75-1.92) .47
Stroke 9 (0.6) 8 (0.4) 0.89 (0.34-2.31) .81
All-cause mortality at 6 mob 41 (2.0) 55 (2.7) 1.35 (0.90-2.02) .15
a A composite of cardiovascular
mortality, nonfatal myocardial
infarction, nonfatal stroke, and
unstable angina with evidence of
ischemia requiring hospitalization at
16 weeks.
b Total number of patients included in
the 6-mo outcomewas 795 for
placebo and 793 for varespladib.
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Figure 4. Comparison of the Effects of Varespladib and Placebo on the Incidence of Primary Composite
Outcome andMyocardial Infarction in Prespecified Subgroup Patient Characteristics
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1.44 (0.93-2.23)
1.16 (0.85-1.58)
1.39 (0.95-2.05)
1.15 (0.83-1.61)
1.04 (0.73-1.46)
1.60 (1.11-2.32)
1.29 (0.86-1.95)
1.23 (0.89-1.69)
1.21 (0.92-1.59)
1.63 (0.85-3.13)
1.36 (0.86-2.15)
1.20 (0.89-1.63)
1.25 (0.79-1.79)
1.25 (0.93-1.69)
1.46 (1.00-2.14)
1.63 (0.77-3.45)
0.998 (0.68-1.46)
P Value for
Interaction
Favors
Varespladib
Favors
PlaceboPatient Characteristics
Age, y
.38
>65
≤65
Sex
.24
Female
Male
Baseline lipid therapy
.17
Yes
No
PCI Postindex event
Yes
No
Diabetes at baseline
Yes
No
Hypertension at baseline
Yes
No
Congestive heart failure
Yes
No
Smoking history
Current smoker
Nonsmoker
Primary indication
.06
.04
.17
.31
.23
.60
NSTEMI
Unstable angina
No. of Patients
VarespladibPlacebo
827 851
1742 1715
660 688
1908 1878
932 915
1622 1639
1616 1679
953 887
801 799
1757 1759
1975 1907
562 629
461 455
2085 2096
858 851
1697 1705
975 959
388 392
1204 1212
No. of Events
VarespladibPlacebo
41 61
69 76
34 50
76 87
45 61
65 75
62 68
48 69
41 52
69 85
95 111
14 25
32 43
78 94
33 41
77 96
45 65
11 18
54 54
No. of Events
VarespladibPlacebo
16 33
32 46
12 28
36 51
16 35
32 43
30 38
18 41
13 30
35 49
38 67
9 11
15 28
33 51
21 26
27 53
18 44
4 9
26 26STEMI
Hazard Ratio
(95% CI)
2.03 (1.12-3.69)
1.45 (0.92-2.28)
2.29 (1.17-4.51)
1.42 (0.93-2.18)
2.26 (1.25-4.09)
1.34 (0.85-2.12)
1.19 (0.73-1.92)
2.55 (1.46-4.43)
2.38 (1.24-4.56)
1.38 (0.89-2.13)
1.82 (1.22-2.71)
1.10 (0.46-2.66)
1.89 (1.08-3.54)
1.53 (0.99-2.38)
1.25 (0.70-2.21)
1.96 (1.23-3.12)
2.47 (1.43-4.28)
2.24 (0.69-7.27)
0.995 (0.58-1.71)
Primary Composite OutcomeA
Myocardial InfarctionB
5.01.00.5
Hazard Ratio (95% CI)
5.01.00.5
Hazard Ratio (95% CI)
The primary efficacy outcomewas a
composite of cardiovascular
mortality, nonfatal myocardial
infarction, nonfatal stroke, and
unstable angina with evidence of
ischemia requiring hospitalization at
16 weeks. Patients were randomized
to receive either varespladib (500
mg/d) or placebo for 16 weeks.
Non-STEMI indicates
non–ST-segment elevation
myocardial infarction; PCI,
percutaneous coronary intervention;
STEMI, ST-segment elevation
myocardial infarction. Because of
missing data, number of patients in
the subgroups do not sum to total
number of patients randomized to
receive placebo or varespladib.
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isoforms.6,7OurfindingswithsPLA2 inhibitionreemphasizethat
identificationofacirculatingmarkerofcardiovascular riskdoes
not necessarily imply that pharmacologic suppression or inhi-
bition of the marker will reduce risk. The failure to demon-
strate any benefit is supported by a recent report fromMendi-
alianrandomizationstudiesconcludingthatsPLA2doesnotplay
acausativerole incoronarydisease16;however,suchstudiescan-
not necessarily predict the result of a pharmacologic interven-
tion in patients with established coronary disease. Ultimately,
most therapies must be tested using careful human random-
ized clinical trials.
The precisemechanism underlying the adverse effect on
the rate of MI with varespladib remains unknown. Recurrent
MI inpatientswitha recentACSoften results fromongoingepi-
sodes of plaque rupture and thrombosis, often at sites re-
mote from the lesion responsible for the initial event. The in-
creased rateofMIobservedearly in the trialmight also suggest
that the drugmay have induced a prothrombotic state. How-
ever, we observed no excess rate of early stent thrombosis in
the varespladib group. In fact, we observed less harm for MI
with varespladib in patients who had undergone percutane-
ous coronary intervention for the index ACS event and in pa-
tients whose initial presentation was with STEMI. There cur-
rently exists no external information regarding potential
interactions between either sPLA2 activity or varespladib and
factors that influence the coagulationcascadeorplatelet func-
tion. Given that other therapies that modulate prostaglandin
metabolites have been reported to be associated with an
excess rate of MI,17 the potential effect of the varespladib
molecule and sPLA2 inhibition on thrombotic and fibrino-
lytic pathways, in addition to plaque stability, require further
investigation.
The findingsmayhave implications for targetingother in-
flammatory pathways as strategies to reduce cardiovascular
risk.Although the roleof vascular inflammation inatheroscle-
rosis iswidely accepted, there is at present no evidence to our
knowledge that targetinganyspecific inflammatory factorwill
attenuate cardiovascular risk. The complexity and redun-
dancyof inflammatorypathwaysmayconfoundsuchefforts.8
Evidence byother studies indicates that interventions target-
ing prostaglandin inflammatory pathways, such as rofecoxib,
are harmful rather than protective against coronary heart
disease.17 Nevertheless, other anti-inflammatory agents, in-
cluding inhibitors of lipoprotein-associatedphospholipaseA2,
are undergoing evaluation in large clinical trials.18-20
Anumberof limitations shouldbenotedwith regard toour
study. Survival status at 6monthswasnot established in ama-
jority of patients. Accordingly, we cannot exclude that the in-
creased rate of MI with varespladib did not ultimately result
in an excess mortality rate. Given that varespladib is a pan-
sPLA2 inhibitor, it is unknownwhether amore selective agent
would be beneficial. Patients were not selected for random-
ization on the basis of their underlying sPLA2 concentration
or activity. The VISTA-16 trial was an evaluation of the effect
of sPLA2 inhibition with varespladib in the first few months
followinganACS. It isunknownwhether suchastrategywould
be more likely to be protective in a more chronic stage of the
disease. However, the finding of an excess risk of MI with va-
respladib makes it unlikely that this will be investigated.
The administrative actions of the sponsor and the time-
lines involved with the dissemination of data from this clini-
cal trial require further comment. The sponsor took the ap-
propriate scientific and ethical course of action to accept the
recommendationby thedata and safetymonitoringboardand
prematurely stop the study for futility onMarch 9, 2012.21 Al-
thoughthestudyprotocol stipulated that survival statuswould
be determined for all patients who participated in the study,
data were collected by the sponsor for only 1588 of the 5145
enrolled patients. In addition, the study steering committee
andthe investigatorsdidnot receive the fulldatabase foranaly-
sis until May 10, 2013, approximately 1 month after the spon-
sor’s compound license expired andwas returned to theorigi-
nal developer of the compound.
Conclusions
In conclusion, sPLA2 inhibition with varespladib administra-
tiondidnot reducecardiovascular ischemiccomplicationsand
resulted in an excess rate of MI and the composite of cardio-
vascular mortality, MI, and stroke in patients with ACS.
Whether this represents an adverse effect of the varespladib
molecule or a consequence of pan-sPLA2 inhibition remains
to be determined.
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Petersburg State Healthcare Institution; City
Hospital 1); Mikhail Arkhipov (State Educational
Institution for Higher Professional Traini); Elena
Ovcharenko (State Healthcare Institution Irkutsk
Regional Clinical Hospi); Galina Guseva (State
Healthcare Institution; Samara Regional Clinical
Cardio); Svetlana Akhunova (State Institution;
Interregional Clinical and Diagn-c Center). Spain:
Antonio Ignacio Fernández Ortiz (Hospital Clinico
San Carlos); Manuel Jiménez Navarro (Hospital
Clinico Universitario Virgen de la Victoria); Antonio
Jose Fernández Romero (Hospital de Alta
Resolucion de Utrera); Iñaki Lekuona Goya
(Hospital de Galdakao); Antoni Serra Peñaranda
(Hospital de la Santa Creu i Sant Pau); Antonio
Amaro Cendon (Hospital de Montecelo); Antoni
Martinez Rubio (Hospital de Sabadell); José Julián
Berrade Zubiri (Hospital General de L'Hospitalet);
Francisco Ridocci Soriano (Hospital General
Universitario de Valencia); Rafael Rubio Sanz
(Hospital General Universitario Gregorio Marañón);
Antonio Bayés Genís (Hospital Germans Trias i
Pujol); Vicente Nieto Lago (Hospital Insular de Gran
Canaria); José Díaz Fernández (Hospital Juan
Ramón Jiménez); Andrés Iñiguez Romo (Hospital
Meixoeiro); Silvestre Nicolás Franco (Hospital Rafael
Méndez); Isabel HernandezMartin (Hospital
Universitari Arnau de Vilanova); Juan Sala Montero
(Hospital Universitari Josep Trueta); Manuel de
Mora Martin (Hospital Universitario Carlos Haya);
Martín Jesús García González (Hospital
Universitario de Canarias); José Maria Serrano
Antolin (Hospital Universitario de Fuenlabrada);
Esteban López de Sá Areses (Hospital Universitario
La Paz); Jesús Martín Miranda (Hospital
Universitario Ntra Sra de la Candelaria); Luís
Alonso-Pulpón (Hospital Universitario Puerta de
Hierro); Gonzalo Barón Esquivias (Hospital
Universitario Virgen del Rocio); Elena Fernández
Jarne (Clínica Universitaria de Navarra); José
Manuel Gutiérrez Cortés (Hospital Arquitecto
Marcide); Maurice Batlle Pérez (Hospital del
Henares); Carlos Lafuente Gormaz (Hospital
General Universitario de Albacete); Jose Maria
Alegret (Hospital Universitari de Sant Joan de
Reus); José Sergio Hevia Nava (Hospital
Universitario Central de Asturias); JuanManuel
Grande Ingelmo (Hospital Universitario Severo
Ochoa); Rafael Hidalgo Urbano (Hospital
Universitario VirgenMacarena); Marcelo Sanmartín
(Policlinico Vigo; S. A. (Povisa).Ukraine:Oleksandr
Katerenchuk (Poltava Regional Cardiological
Dispensary); Igor Vakaliuk (Ivano-Frankivsk
Regional Clinical Ñardiological Dispensary);
Oleksandr Karpenko (Kyiv City Clinical Hospital No.
1); Oleksandr Prokhorov (City Clinical Hospital No.
27); Olena Koval (Clinical Joint Emergency
Hospital); Andriy Faynyk (Clinical
Treatment-and-Diagnostic Cardiology Center);
Mykola Kopytsya (Institute of Therapy named after
L. T. Malaya); Yuriy Karpenko (Odessa Regional
Clinical Hospital); Igor Kraiz (Central Clinical
Hospital of Ukrzaliznytsya); Olexander Feskov
(Kharkiv City Clinical Hospital of Emergency Care);
Leonid Rudenko (Kyiv City Clinical Hospital of
Emergency Care); Sergii Kozhukhov (M. D.
Strazhesko Institute of Cardiology); Borys
Goloborodko (Public Institution–City Clinical
Hospital No. 3).United States: Ernesto Rivera
(Amarillo Heart Clinical Research Institute Inc);
Stephen Broadwater (Augusta Cardiology Clinic
PC); Stephen Crowley (Aurora Denver Cardiology
Associates); Nampalli Vijay (Aurora Denver
Cardiology Associates PC); Rajiv Goswami (Ben
Taub General Hospital); L. Norman Ferrier (Black
Hills Cardiovascular Research); Arnoux Blanchard
(Broward General Medical Center); Kevin McCullum
(Cardiac Diagnostic Associates PC); Richard
Chernick (Cardiology Associates Department of
Clinical Research); Barry Bertolet (Cardiology
Associates Research LLC); Joseph Battaglia
(Cardiology PC); John Richardson (Cardio-Thoracic
Surgeons; PC); Stanley Lochridge (Cardio-Thoracic
Surgeons; PC East); Scott Lieberman
(Cardiovascular Associates of East Texas); Ali
Amkieh (Cardiovascular Associates Research LLC);
James Bradley Cavender (Cardiovascular Associates
PC); Stephen Denning (Cardiovascular Consultants
Aultman Hospital); Charles Treasure
(Cardiovascular Research of Knoxville); James
Kmetzo (Central Bucks Cardiology); Michael
Stillabower (Christiana Care Health System);
Emmanouil Brilakis (Dallas VAMedical Center);
Gregory Schwartz (Denver VAMedical Center);
Roger Acheatel (Escondido Cardiology Associates);
Eugene Kukuy (Crescent City Cardiovascular); Majdi
Ashchi (First Coast Cardiovascular Institute PA);
Kimberly Skelding (Geisinger Clinic); Lisa Martin
(GeorgeWashington University Medical Faculty
Assoc); Eve Gillespie (Glacier View Cardiology);
William French (Harbor–UCLAMedical Center);
Stewart Pollock (Harrisonburg Medical Associates);
Donna Polk (Hartford Hospital); Robert Black
(Heart & Vascular Institute of Florida); David
Drenning (Heart Center Research LLC); Jerome
Anderson (Integris Baptist Medical Center); Mark
Sanz (International Heart Institute of Montana); Elie
Korban (Kore CV Research); MarkWiley (KUMC
Research Institute Inc); Shereif Rezkalla (Marshfield
Clinic); AnthonyMinisi (McGuire VAMC; Code 151);
Ahmed Shah (Mercer University School of
Medicine); Paul Silverman (MidAmerica
Cardiovascular Consultants); Mohamadali Amlani
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(Mid-Michigan Cardiology Associates PLC); Gregory
Eaton (Mid-Ohio Heart Clinic Inc); Alan Brown
(Midwest Heart Specialists); Desmond Jay
(Minneapolis Heart Institute Foundation); Arthur
Loussararian (Mission Internal Medical Group);
Gervasio Lamas (Mount Sinai Medical Center);
Michael Lauer (Northwest Michigan Heart and
Vascular Specialist); JeromeWilliams (Novant
Medical Group Inc); Abedelrahim Asfour (Oakwood
Hospital &Medical Center Dearborn); Lars Runquist
(Palmetto Medical Research); Roy Robertson
(Parkview Research Center); Ronald Blonder (Pikes
Peak Cardiology); Crispin Davies (Portland VA
Medical Center); Thomas Downes (Poudre Valley
Medical Group Heart Center of the Rockies); Nicolas
Chronos (Saint Joseph's Research Institute); Steve
Marso (Saint Lukes); Thomas Haldis (Sanford
Research/USD); David Eich (Sentara Cardiovascular
Research Institute); Mudassar Ahmed (SMDC Heart
and Vascular Center); Cara East (Soltero
Cardiovascular Research Center); LeeMacDonald
(South Denver Cardiology Associates PC); Paul
Seigel (South Florida Research Group LLC); Michael
White (The Cardiac Center of Creighton University);
Alan Camp (the Heart and Vascular Institute of
Florida); Neal Kleiman (theMethodist Hospital
Research Institute); Douglas Burtt (the Miriam
Hospital); Janet Strain (the Valley Hospital); Brian
Go (Triangle Medical Research); Phillip Henry
(TriCities Medical Research); Parvez Sultan (Trinity
Medical Center); Patrice Delafontaine (Tulane
University Health Sciences Center); Hisham Kashou
(UHS Office of Clinical Trials); Charles Lambert
(University Community Hospital); M. Reza Movahed
(University of Arizona); Jorge Saucedo (University
of Oklahoma Health Sciences Center); Udho
Thadani (VAMedical Center); Yellapraguda
Chandrashekhar (VAMedical Center); David Lu
(VAMC); Harish Chandna (Victoria Heart and
Vascular Center); JamesMann (Wake Heart
Research); Geetha Ramaswamy (Washington
Regional Medical Center); Kevin Browne (Watson
Clinic LLP); Matthew Janik (WilmingtonMedical
Research); Kevin Cannon (WilmingtonMedical
Research); Paul Tolerico (York Hospital).
Correction: The forest plots in both panels of
Figure 4 were corrected on December 20, 2013.
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